NEW YORK (GenomeWeb News) — SeqWright today said it will perform all of the sequencing and analysis for a set of clinical trials being conducted by Third Wave Technologies.
Third Wave is developing two in vitro molecular assays and a genotyping test to screen for human papillomavirus, which has been identified as the cause of approximately 70 percent of cervical cancer cases, SeqWright said.
Third Wave’s tests will detect and identify 14 HPV high-risk types and HPV types 16 and 18, the company said.
SeqWright uses gene sequencing and bioinformatics technologies to help companies run clinical trials for FDA submission.